Data highlight potential of Cloudbreak immunotherapy candidates
for the treatment of multi-drug resistant Gram-negative bacterial
infections
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that new data highlighting the company’s innovative
Cloudbreak™ immunotherapy discovery platform will be presented at two
upcoming conferences. Cloudbreak is a novel platform that pairs potent
antimicrobials with agents that redirect the immune system to destroy
fungal, bacterial and viral pathogens.
Presentations highlighting data from pre-clinical studies of Cloudbreak
candidates targeted at multi-drug resistant (MDR) Gram-negative
pathogens will be delivered at the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID)/American Society for
Microbiology (ASM) Conference on Drug Development to Meet the Challenge
of Antimicrobial Resistance, taking place in Lisbon, Portugal, September
4-7, 2018, and the 16th Annual Discovery on Target Meeting,
taking place in Boston, September 25-28, 2018.
Gram-negative pathogens are responsible for half of all healthcare
associated infections (HAIs) and the primary cause of HAIs in intensive
care units (ICU). The Centers for Disease Control and Prevention (CDC)
estimates that there were 1.7 million total HAIs in the United States
and the estimated number of deaths associated with HAIs was 99,000,
costing the U.S. health care system $20 billion per year.
“These presentations highlight the prospect of our Cloudbreak
immunotherapy platform as a new approach to treat and prevent serious
multi-drug resistant Gram-negative bacterial infections,” said Jeffrey
Stein, Ph.D., president and chief executive officer of Cidara. “Just as
immunotherapies have revolutionized the treatment of cancer, we believe
that our bispecific Cloudbreak agents have the potential to
fundamentally change the treatment of infectious diseases.”
The ESCMID/ASM conference is a multidisciplinary meeting addressing the
challenges, opportunities and current requirements related to drug
development for antimicrobial resistance. The Discovery on Target
conference convenes over 1,300 drug discovery professionals and focuses
on topics related to current and emerging “hot” targets, technologies
and validation strategies for the development of novel small molecules
and biologics.
Details of the presentations at each meeting are as follows:
ESCMID/ASM Conference
Poster Category: Drug Development
Poster Title:
Characterization of novel cyclic polypeptides with potent in vitro
and in vivo activity against multi-drug resistant Gram-negative
pathogens, and with reduced nephrotoxicity relative to colistin
Abstract
number: 57
Date and time: Tuesday, September 4,
9:50 a.m. Western European Time (Poster will be on display throughout
the event, September 4-7.)
Location: Intercontinental Lisbon
Discovery on Target Conference
Oral Session: Alternative Therapies
Oral Presentation
Title: Cloudbreak antibody-drug conjugates for treatment of MDR
Gram-negative bacterial infections
Date and time: Wednesday,
September 26, 2:15 p.m. Eastern Time
Presenter: James
Levin, Ph.D., Director of Preclinical Development, Cidara Therapeutics
Location:
Sheraton Boston
Copies of these presentations will be available on the Cidara website
following the meetings: www.cidara.com
About Cloudbreak
The Cloudbreak immunotherapy platform is a fundamentally new approach
for the treatment of infectious disease that, in a single molecule,
pairs potent antimicrobials with agents that redirect the immune system
to destroy fungal, bacterial and viral pathogens. Cidara is initially
developing Cloudbreak candidates for the treatment and prevention of
serious multi-drug resistant (MDR) Gram-negative bacterial infections.
These include Cloudbreak Antibody Drug Conjugates (ADC) which have the
potential to offer several added benefits over small molecule approaches
for use as highly effective countermeasures against MDR bacterial
infections. Different from traditional antibiotics, the Cloudbreak ADCs
physically link the pathogen and the immune component to eradicate
pathogens via dual killing mechanisms.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate,
formerly known as CD101 IV, through clinical trials. Rezafungin has
improved pharmacokinetics compared to existing echinocandins and the
potential for expanded utility across patient settings. It is the only
once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections. The company’s
Phase 2 STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and provides support for Cidara to initiate Phase 3
pivotal trials in the treatment of candidemia and invasive candidiasis
and the prophylaxis of invasive fungal infections. Cidara also is
leveraging its novel Cloudbreak™ platform to develop antibody-drug
conjugates for the treatment of multi-drug resistant Gram-negative
bacterial infections. Cloudbreak is the first immunotherapy discovery
platform designed specifically to create compounds that directly kill
pathogens and also direct a patient’s immune cells to attack and
eliminate bacterial, fungal or viral pathogens. Cidara is headquartered
in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, the potential for the Cloudbreak immunotherapy platform to treat and
prevent serious multi-drug resistant Gram-negative bacterial infections
and to fundamentally change the treatment of infectious diseases. Risks
that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180904005018/en/
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
